TAT-Cx43266-283

TAT-Cx43266-283 is a cell-penetrating peptide designed to inhibit Src kinase activity by mimicking the Src-binding domain of Connexin43 (Cx43). Developed primarily by researchers at the University of Salamanca and the Cleveland Clinic, this peptide specifically targets glioblastoma stem cells (GSCs), which are responsible for tumor recurrence and resistance to standard therapies like temozolomide. By inhibiting Src, TAT-Cx43266-283 reduces GSC proliferation, invasion, and self-renewal. Preclinical studies have demonstrated that intracranial administration of the peptide, particularly when combined with surgical resection, extends survival in glioblastoma-bearing mouse models by increasing tumor cell apoptosis and reducing aberrant vascularization. The peptide consists of the TAT cell-penetrating sequence fused to residues 266-283 of the C-terminal domain of Connexin43.

Other names

Src-inhibitory peptide TAT-Cx43266-283